What is the recommended dose and administration instructions for Tamiflu (Oseltamivir)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tamiflu (Oseltamivir) Dosing and Administration

Treatment Dosing

For adults and adolescents ≥13 years, administer oseltamivir 75 mg orally twice daily for 5 days, initiated within 48 hours of symptom onset for maximum effectiveness. 1, 2

Adults and Adolescents (≥13 years)

  • Standard dose: 75 mg orally twice daily for 5 days 1, 2
  • Treatment must be started within 48 hours of symptom onset 3, 4

Pediatric Patients (≥12 months to 12 years)

Weight-based dosing twice daily for 5 days: 1, 2

  • ≤15 kg (≤33 lb): 30 mg twice daily
  • 15-23 kg (>33-51 lb): 45 mg twice daily

  • 23-40 kg (>51-88 lb): 60 mg twice daily

  • 40 kg (>88 lb): 75 mg twice daily

Infants (0-11 months)

Age-based dosing twice daily for 5 days: 1

  • 9-11 months: 3.5 mg/kg per dose twice daily
  • Term infants 0-8 months: 3 mg/kg per dose twice daily

Preterm Infants

Postmenstrual age-based dosing (gestational age + chronological age) twice daily for 5 days: 1, 3

  • <38 weeks: 1.0 mg/kg twice daily
  • 38-40 weeks: 1.5 mg/kg twice daily
  • 40 weeks: 3.0 mg/kg twice daily

Prophylaxis Dosing

Post-Exposure Prophylaxis

Initiate within 48 hours of contact with infected individual: 1, 2

  • Adults/adolescents ≥13 years: 75 mg once daily for 10 days 1
  • Pediatric patients ≥1 year: Same weight-based doses as treatment, but once daily for 10 days 1
  • Infants 3-11 months: 3 mg/kg once daily for 10 days 1
  • Prophylaxis is NOT recommended for infants <3 months unless critical situation 3

Seasonal Prophylaxis

  • Duration: Up to 6 weeks during community outbreak 2
  • Immunocompromised patients: May continue up to 12 weeks 2

Renal Impairment Adjustments

For creatinine clearance 10-30 mL/min: 1, 3

  • Treatment: 75 mg once daily for 5 days
  • Prophylaxis: 30 mg once daily for 10 days OR 75 mg every other day for 10 days (5 total doses)

Not recommended for end-stage renal disease patients not on dialysis 2

Formulations and Administration

Available Forms

  • Capsules: 30 mg, 45 mg, 75 mg 1, 4
  • Oral suspension: 6 mg/mL when reconstituted 1, 4

Suspension Dosing Volumes

1

  • 30 mg dose = 5 mL
  • 45 mg dose = 7.5 mL
  • 60 mg dose = 10 mL
  • 75 mg dose = 12.5 mL

Administration Instructions

  • Can be taken with or without food 3, 4, 2
  • Taking with food improves gastrointestinal tolerability and reduces nausea/vomiting 3, 4
  • Capsules can be opened and mixed with liquid if patient cannot swallow whole 3
  • If commercial suspension unavailable, pharmacies can compound from capsules to 6 mg/mL concentration 3

Special Populations

Pregnancy and Breastfeeding

  • Pregnant women receive same dosing as non-pregnant adults: 75 mg twice daily for 5 days 1
  • Safe throughout all trimesters and postpartum period (within 2 weeks after delivery) 1
  • Breastfeeding mothers can receive oseltamivir; not a reason to discontinue breastfeeding 1

Critical Drug Interactions

Avoid live attenuated influenza vaccine (LAIV) within 48 hours before oseltamivir use 1, 3

Do not use oseltamivir for 14 days after LAIV vaccination 1, 3

Common Adverse Effects

  • Nausea and vomiting (5-15% of patients) 3, 5
  • Gastrointestinal effects including diarrhea 3
  • Headache and skin reactions may occur 3
  • Effects are typically mild and transient 5

Clinical Pearls

  • Earlier initiation of therapy (within 48 hours) associated with faster symptom resolution 4, 5
  • Treatment reduces illness duration by up to 1.5 days and severity by up to 38% 5
  • Reduces secondary complications and antibiotic use 5
  • Higher doses (150 mg twice daily) show no additional benefit for influenza A but may improve response in influenza B 6

References

Guideline

Oseltamivir Dosing Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Oseltamivir Dosage and Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Oseltamivir and Peramivir Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.